Antithrombin III and local serum application: Adjuvant therapy in peritonitis

European Journal of Clinical Investigation

Volumn 30, Issue 4, 2000, Pages 359-366

  Schorr, Markus ^a,c   Siebeck, M ^a,c   Zugel N ^b,d   Welcker, K ^a,c   Gippner Steppert, C ^a,c   Czwienzek, E ^a,c   Groschler M ^a,c   Jochum, M ^a,c  

^a UNIVERSITY OF MUNICH   (Germany)

^b KLINIKUM AUGSBURG   (Germany)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^d Klinik fur Allgemein und Viszeralchirurgie   (Germany)

Author keywords

Antithrombin III; Opsonization; Organ failure; Peritonitis; Proteinase inhibitor; Serum

Indexed keywords

ANTITHROMBIN III;

ADULT; AGED; ARTICLE; BLOOD TRANSFUSION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; MALE; MORTALITY; MULTIPLE ORGAN FAILURE; PERITONITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

ADULT; ANTITHROMBIN III; APACHE; BLOOD COMPONENT TRANSFUSION; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; INTENSIVE CARE; MALE; PERITONITIS; PROSPECTIVE STUDIES;

EID: 0034010634     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2362.2000.00630.x     Document Type: Article

References (37)

1. 1 Koperna T, Schulz F. Prognosis and treatment of peritonitis. Do we need new scoring systems? Arch Surg 1996;131:180-6.
2. 2 Edmiston CE Jr, Goheen MP, Kornhall S, Jones FE, Condon RE. Fecal peritonitis: microbial adherence to serosal mesothelium and resistance to peritoneal lavage. World J Surg 1990;14:176-83.
3. 3 Billing A, Kortmann H, Fröhlich D, Jochum M. Breakdown of C3 complement and IgG in peritonitis exudate -pathophysiological aspects and therapeutic approach. Prog Clin Biol Res 1989;308:527-33.
4. 4 Siebeck M. Thrombin Inhibition. In: E. Faist, editor. The immune consequences of trauma, shock and sepsis mechanisms and therapeutic approaches. Lengerich; Berlin; Düsseldorf; Riga; Scottsale (USA); Wien; Zagreb Pabst Science Publishers;1996:2/2:1210-1217.
5. 5 Jochum M. Influence of high-dose antithrombin concentrate therapy on the release of cellular proteinases, cytokines, and soluble adhesion molecules in acute inflammation. Semin Hematol 1995;32 (4) (Suppl. 2):19-32.
6. 6 Blajchman MA. An overview of the mechanism of action of antithrombin and its inherited deficiency states. Blood Coagul Fibrinolysis 1994;5 (Suppl. 1):S5-11; discussion S59-64.
7. 7 Buller HR, ten Cate JW. Acquired antithrombin III deficiency: laboratory diagnosis, incidence, clinical implications, and treatment with antithrombin III concentrate. Am J Med 1989;87 (3B):44S-48S.
8. 8 Fourrier F, Chopin C, Goudemand J, Hendrycx S, Caron C, Rime A et al. Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies. Chest 1992;101:816-23.
9. 9 Taylor FB Jr, Emerson TE Jr, Jordan R, Chang AK, Blick KE. Antithrombin III prevents the lethal effects of Escherichia coli infusion in baboons. Circ Shock 1988;26:227-35.
10. 10 Emerson TE. Effects of purified fibronectin alone and combined with immunogobulin G or antithrombin III on survival during gram negative peritonitis or endotoxemia in rats. J Trauma 1987;27:1261-6.
11. 11 Emerson TE Jr, Fournel MA, Redens TB, Taylor FB Jr. Efficacy of antithrombin III supplementation in animal models of fulminant Escherichia coli endotoxemia or bacteremia. Am J Med 1989;87 (3B):27S-33S.
12. 12 Emerson TE Jr. Antithrombin III replacement in animal models of acquired antithrombin III deficiency. Blood Coagul Fibrinolysis 1994;5 (Suppl. 1):S37-45; discussion S59-64.
13. 13 Dickneite G, Paques EP. Reduction of mortality with antithrombin III in septicemic rats: a study of Klebsiella pneumoniae induced sepsis. Thromb Haemost 1993;69:98-102.
14. 14 Uchiba M, Okajima K, Murakawi K, Okabe H, Takatsuki K. Attenuation of endotoxin-induced pulmonary vascular injury by antithrombin III. Am J Physiol. 1996:270 (Lung Cell Mol Physiol:14):L921-L930.
15. 15 Blauhut B, Necek S, Vinazzer H, Bergmann H. Substitution therapy with an antithrombin III concentrate in shock and DIC. Thromb Res 1982;27:271-8.
16. 16 Blauhut B, Kramar H, Vinazzer H, Bergmann H. Substitution of antithrombin III in shock and DIC. a randomized study. Thromb Res 1985;39:81-9.
17. 17 Maki M, Terao T, Ikenoue T, Takemura T, Sekiba K, Shirakawa K et al. Clinical evaluation of antithrombin III concentrate (BI 6.013) for disseminated intravascular coagulation in obstetrics. Well controlled multicenter trial. Gynecol Obstet Invest 1987;23:230-40.
18. 18 Schwartz RS, Bauer KA, Rosenberg RD, Kavanaugh EJ, Davies DC, Bogdanoff DA. Clinical Experience with antithrombin III concentrate in treatment of congenital and acquired deficiency of antithrombin III. Am J Med., 1989;87 (suppl. 13 B):535-605.
19. 19 Seitz R, Wolf M, Egbring R, Havemann K. The disturbance of hemostasis in septic shock: role of neutrophil elastase and thrombin, effects of antithrombin III and plasma substitution. Eur J Haematol 1989;43:22-8.
20. 20 Fourrier F, Lestavel P, Chopin C, Marey A, Goudemand J, Rime A et al. Meningococcemia and purpura fulminans in adults: acute deficiencies of proteins C and S and early treatment with antithrombin III concentrates. Intensive Care Med 1990;16:121-4.
21. 21 Seitz R, Egbring R. Patients with septic shock: antithrombin III supplementation. Biomed Prog 1992;5:27-9.
22. 22 Albert J, Blomqvist H, Gardlund B, Jakobsson J, Svensson J, Blomback M. Effect of antithrombin concentrate on haemostatic variables in critically ill patients. Acta Anaesthesiol Scand 1992;36:745-521.
23. 23 Menache D, Grossmann BJ, Jackson CM. Review. Antithrombin III. physiology, deficiency, and replacemant therapy. Transfusion 1992;32:580-8.
24. 24 Fourrier F, Chopin C, Huart JJ, Runge I, Caron C, Goudemand J. Double blind, placebo controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation. Chest 1993;104: 882-8.
25. 25 Schuster HP. AT III in septicemia with DIC. Intensive Care Med 1993;19 (Suppl. 1) (S16):8.
26. 26 van Beek EJ, von der Mohlen MA, ten Cate JW, Brandjes DP, Buller HR. Antithrombin III concentrate in the treatment of DIC. a retrospective follow up study. Neth J Med 1994;45:206-10.
27. 27 Diaz Cremades JM, Lorenzo R, Sanchez M, Moreno MJ, Alsar MJ, Bosch JM et al. Use of antithrombin III in critical patients. Intensive Care Med 1994;20:577-80.
28. 28 Eisele B, Lamy M. Clinical experience with antithrombin III concentrates in critically ill patients with sepsis and multiple organ failure. Semin Thromb Hemost 1999;24:71-80.
29. 29 Inthorn D, Hoffmann JN, Hartl WH, Mühlbayer D, Jochum M. Antithrombin III supplementation in severe sepsis: Beneficial effects on organ dysfunction. Shock 1997;8:328-34.
30. 30 Waydhas Ch, Nast-Kolb D, Gippner-Steppert C, Trupka A, Pfundstein Ch, Schweiberer L et al. High-dose antithrombin III treatment of severely injured patients: Results of a prospective study. J Trauma 1998;45:931-9.
31. 31 Billing AG, Frohlich D, Konecny G, Schildberg FW, Machleidt W, Fritz H et al. Local serum application: restoration of sufficient host defense in human peritonitis. Eur J Clin Invest 1994;24:28-35.
32. 32 Nystrom PO, Bax R, Dellinger EP, Dominioni L, Knaus WA, Meakins JL et al. Proposed definitions for diagnosis, severity scoring, stratification, and outcome for trials on intra-abdominal infection. Joint Working Party of SIS North America and Europe. World J Surg 1990;14:148-58.
33. 33 Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II. a severity of disease classification system. Crit Care Med 1985;13:818-29.
34. 34 Linder MM, Wacha H, Feldmann U, Wesch G, Streifensand RA, Gundlach E. The Mannheim peritonitis index. An instrument for the intraoperative prognosis of peritonitis. Chirurg 1987;58:84-92.
35. 35 Goris RJ, te Boekhorst TP, Nuytinck JK, Gimbrere JS. Multiple organ failure. Generalized autodestructive inflammation? Arch Surg 1985;120:1109-15.
36. 36 Vincent JL, Moreno R, Takala J, Willatts S, De Mendonca A, Bruining H et al. The SOFA (Sepsis related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 1996;22:707-10.
37. 37 Baue AE, Durham R, Faist E. Systemic inflammatory response syndrome (SIRS), mulitple organ function syndrome (MODS), multiple organ failure (MOF): are we winning the battle? Shock 1998;10:79-89.